Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...